-transparent.png){kind=logo}
A mouse interferon alpha gene (MuIFN-alpha 10) was isolated from a BALB/c cosmid genomic library. The gene was located on a 1.8 kb HindIII fragment and a 5.1 kb EcoRI fragment. The coding region and parts of the 5' and 3' non-coding regions were sequenced. The results showed that the MuIFN-alpha 10 gene encoded a protein of 167 amino acids. Like most other MuIFN-alpha species it contained a putative N-glycosylation site at amino acid positions 78 to 80. It also possessed cysteine residues at positions 1, 29, 86, 99 and 129. In the signal peptide, in addition to cysteine 21, which is present in all MuIFN-alpha species sequenced so far, a cysteine was found at position 22. At the amino acid level MuIFN-alpha 10 showed strong homology to MuIFN-alpha 1 (only 15 out of 167 amino acids were different). The MuIFN-alpha 10 gene was transiently expressed in monkey COS cells under the direction of the simian virus 40 early promoter. The protein product secreted by COS cells was equally active on mouse (L929) and hamster (CHO) cells. However, as compared to MuIFN-alpha 1 and MuIFN-alpha 4 the specific activity on mouse cells of the protein was 10- to 100-fold lower. To find out which region of its structure was responsible for this low activity, hybrids of the genes encoding MuIFN-alpha 10 and MuIFN-alpha 1 were constructed using the two common XmmI sites which correspond to positions between amino acids 67 and 68 and 123 and 124, respectively. The data showed that hybrid constructs which were MuIFN-alpha 1-like from amino acid 68 or MuIFN-alpha 10-like from position 124 to the C terminus possessed high antiviral activity. Other hybrid constructs were hardly active at all. This implied that the amino acid 68 to 123 region was mainly responsible for the low antiviral activity of MuIFN-alpha 10. In this part of the molecule MuIFN-alpha 1 and MuIFN-alpha 10 differed in only five amino acids. A serine at position 110 and a valine at 85 were unique to MuIFN-alpha 10 as compared to all known MuIFN-alpha and human IFN-alpha subspecies.
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
January 1986,
Gene,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
August 1986,
The Journal of general virology,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
December 1984,
Journal of biological response modifiers,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
June 1992,
Annals of the New York Academy of Sciences,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
April 1982,
Biochemical and biophysical research communications,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
October 1986,
The Journal of general virology,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
January 1990,
Doklady Akademii nauk SSSR,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
June 1988,
The Journal of biological chemistry,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
February 2003,
Journal of medical virology,
J Trapman, and
M van Heuvel, and
P de Jonge, and
I J Bosveld, and
P Klaassen, and
E C Zwarthoff
August 1994,
Biochemical and biophysical research communications,
